Advertisement

Organisation › Details
Immatics N.V. (Nasdaq: IMTX)
![]() |
Start | 2020-03-17 planned |
Group | Immatics (Group) | |
![]() |
Industry | cancer drug |
Industry 2 | ACTengine® cell therapy product | |
![]() |
Person | Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder) |
Person 2 | Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst) | |
![]() |
Region | Netherlands_oo |
Country | Netherlands | |
City | n. a. | |
Address record changed: 2020-03-19 | ||
Basic data | Employees | D: 101 to 500 (2021-12-31) |
Currency | EUR | |
Annual sales | 35,088,000 (revenue, consolidated (2021) 2021-12-31) | |
Profit | -93,335,000 (2021-12-31) | |
Cash | 132,994,000 (2021-12-31) | |
Record changed: 2022-10-10 |
Advertisement

More documents for Immatics (Group)
- [1] Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen....
- [2] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
- [3] Immatics N.V.. (9/10/22). "Press Release: Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022". Houston, TX & Tübingen....
- [4] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
- [5] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....
- [6] Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX....
- [7] Immatics N.V.. (6/7/22). "Press Release: Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer". Tübingen, Houston, T...
- [8] Immatics N.V.. (6/2/22). "Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs". Tübingen, Houston, TX & New York, NY....
- [9] Immatics N.V.. (3/23/22). "Press Release: Immatics Announces Full Year 2021 Financial Results and Corporate Update". Tübingen & Houston, TX....
- [10] Immatics N.V.. (12/14/21). "Press Release: Immatics and Bristol Myers Squibb Enter into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401". Tübingen, Houston, TX & New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
» top